Skip to main content
. 2021 Feb 19;12(2):203. doi: 10.1038/s41419-021-03492-3

Fig. 1. GBP5 is upregulated in GBM tumors and cell lines and predicts poor prognosis.

Fig. 1

A Immunoblot analysis of GBP5 in human GBM patient samples and normal brain tissues. GAPDH was used as loading control. B Immunoblot analysis of GBP5 in human glioma cell lines, immortalized normal astrocyte NHA, and immortalized primary human fetal astrocyte IPHFA cells. GAPDH was used as loading control. C Cancer Genome Atlas (TCGA) dataset analysis of the GBP5 mRNA expression levels in GBM subtypes and normal brain tissues. **p < 0.01; ***p < 0.001. Normal: n = 9; Neural (NE): n = 27; classical (CL): n = 80; mesenchymal (ME): n = 96. D TCGA dataset analysis of the relationship between the expression levels of GBP5 and the prognosis of GBM patients. p = 0.015. n = 331.